Vagus nerve stimulation

Vagus nerve stimulation reduces inflammation in children with Inflammatory Bowel Disease, Feinstein Institutes study finds

Retrieved on: 
Wednesday, October 18, 2023
Research, Managed Care, General Health, Consumer, Medical Devices, Children, Science, Biotechnology, Neurology, Practice Management, Other Science, Health, Abdominal pain, Child, MRI, Medical research, Feinstein, Inflammation, Feinstein Institutes for Medical Research, Cohen, FC, Vagus nerve, Weatherall Institute of Molecular Medicine, Heart rate, Diarrhea, Human, Medicine, Prevalence, Vagus nerve stimulation, Incontinence, Diabetes, Rheumatoid arthritis, MBA, Electricity, TENS, Bleeding, GE Research, Ulcerative colitis, Multimedia, Northwell Health, Disease, Clinical trial, Nature Communications, Pulmonary hypertension, Neuroscience, Ear, Arthritis, IBD, Sickle Cell Anemia, a Molecular Disease, Credit, Molecular medicine, Brain, Cancer, Patient, Liver disease, Biomedical engineering, Bangladesh Technical Education Board, MS, Central nervous system, Lupus, Medical imaging, Pharmaceutical industry, Management, Gastroenterology, MD

View the full release here: https://www.businesswire.com/news/home/20231018401966/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018401966/en/
    The Feinstein Institutes for Medical Research’s Dr. Benjamin Sahn led the vagus nerve stimulation clinical trial.
  • Inflammation and the inflammatory reflex – the neuronal signaling between the brain and body – is an important immune response.
  • Previous research and functional MRI studies have mapped stimulation of the auricular branch of the vagus nerve to activate the same brain regions as implanted devices, confirming this nerve as a suitable non-invasive target to administer vagus nerve stimulation.
  • Also, Feinstein Institutes researchers, in collaboration with GE Research, published research that harnessed ultrasound technology to reduce inflammation in the body non-invasively.

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Monday, October 16, 2023
Research, General Health, Pharmaceutical, Philanthropy, Fund Raising, Foundation, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, VNS, MBA, Doctor of Philosophy, Litre, Indian Council of Medical Research, Bleeding, Anemia, Sickle cell disease, MD, Northwell Health, Injury, Von Willebrand disease, VWD, Electricity, Vagus nerve stimulation, Medical research, Desmopressin, Feinstein Institutes for Medical Research, Coagulopathy, Haemophilia, Scientific Advisory Group, Tan, Hemostasis, Nature Communications, Cyclic permutation, Blood, Vagus nerve, Patient, Pharmaceutical industry, Medical device, The New York Times, Cure, Pathway

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Clinical Trials, Medical Devices, RA, Defecation, TNF, Gastrointestinal tract, Vagus nerve, Serum, Disease, Quality of life, Vagus nerve stimulation, Inflammation, Doctor of Philosophy, Rheumatoid arthritis, Inflammatory bowel disease, Crohn's disease, Journal, Medical director, MD, Patient, Gastroenterology, CDAI, Safety, Northwestern, Pharmaceutical industry, Colitis, Medicine

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .
  • The pilot study demonstrated that neuroimmune modulation via vagus nerve stimulation resulted in a clinically meaningful reduction in disease activity and improved quality of life.
  • “Crohn’s disease is a debilitating inflammatory condition affecting the gastrointestinal tract.
  • “We are committed to advancing the potential of neuroimmune modulation for patients suffering from various chronic autoimmune conditions,” said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical.

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Retrieved on: 
Thursday, September 14, 2023
Insulin, Type 2 diabetes, Obesity, Vagus nerve, SBIR, Weight loss, Pancreas, Vagus nerve stimulation, Diabetes, Electrode, Blood, Alloxan, Hypoglycemia, Animal, Reshaping Cultural Policies, EUS, Bluetooth, Liver, AI, Research, NIH, Pharmaceutical industry, Medical device

Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.

Key Points: 
  • Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.
  • “ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose.
  • Increased glycemic control, has been successfully demonstrated in a Zucker rat model of Type 2 diabetes as well as in an alloxan treated swine model of type 2 diabetes, both of which were completed with the help of an initial NIH grant,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®.
  • The promise of the DBSN™ device is evidenced, not only by the volume of NIH funding, but also by the presentation of compelling preclinical evidence at multiple medical conferences.

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Retrieved on: 
Wednesday, August 16, 2023
Health, Hospitals, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, System, Institutional review board, Feinstein Institutes for Medical Research, Biomedical Research, Vagus nerve stimulation, Data analysis, IRB, Human, Feinstein, FDA, Medical research, Pharmaceutical industry, Medical device

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board (“IRB”) and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.
  • An IRB is an FDA-registered group that has been formally designated to review and monitor biomedical research involving human subjects.
  • In collaboration with Tivic Health, The Feinstein Institutes for Medical Research has initiated the recruitment and completed the first patient enrollment of subjects in the study.
  • This study may provide greater targeting strategies of stimulation and more control over the types of physiologic effects that result from stimulation.

Tivic Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Nursing, Health, Medical Devices, Neurology, Health Technology, Managed Care, General Health, System, Insurance, Letter, Feinstein Institutes for Medical Research, Marketing, Bank statement, Telephone, Vagus nerve stimulation, Cardinal Health, Ernst, Rheumatology, CFO, Growth, Cardiology, Research, Medical research, Video game, Renewable energy, Pharmaceutical industry, Management, Cryptocurrency, Webcast

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”).

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 (“Q2 2023”).
  • Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second quarter of 2022.
  • Net loss of $2.1 million in the second quarter of 2023, compared with $3.0 million in the second quarter of 2022.
  • The company’s MD&A and consolidated financial statements for the second quarter ended June 30, 2023, will be filed on August 14, 2023, with the company’s Quarterly Report on Form 10-Q.

Evren Technologies Announces Launch of Revolutionary Phoenix®100 System for Vagus Nerve Stimulation Research

Retrieved on: 
Thursday, July 13, 2023
VNS, Sympathetic nervous system, Vagus nerve, MBA, Research, Brain, Vagus nerve stimulation, MSE, Evren, Patient, Risk, Protocol, PTSD, Calibration, Television, Medical device, Phoenix

GAINESVILLE, Fla., July 13, 2023 /PRNewswire/ -- Evren Technologies, an innovator in the field of medical neuromodulation devices, today announced the launch of its pioneering Phoenix® 100 System, a state-of-the-art transcutaneous auricular vagus nerve stimulator (taVNS) research tool.

Key Points: 
  • GAINESVILLE, Fla., July 13, 2023 /PRNewswire/ -- Evren Technologies, an innovator in the field of medical neuromodulation devices, today announced the launch of its pioneering Phoenix® 100 System, a state-of-the-art transcutaneous auricular vagus nerve stimulator (taVNS) research tool.
  • Evren Technologies announced the launch of its pioneering Phoenix® CR-100 System, a state-of-the-art research tool.
  • The Phoenix 100 System solves long-standing challenges faced by researchers in the realm of Vagus Nerve Stimulation (VNS).
  • The Phoenix 100 stimulates the vagus nerve via the ear's pinna, downregulating the sympathetic nervous system to reduce stress response.

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

Retrieved on: 
Thursday, July 6, 2023
VNS, Male, Von Willebrand disease, Partnership, Depression, Bleeding, Nature, Litre, VWD, Urine, Feinstein Institutes for Medical Research, Tan, Anxiety, Anovulatory cycle, Clinical trial, Nature Communications, Haemophilia, Vagus nerve stimulation, Research, Northwell Health, Desmopressin, Cyclic permutation, Bruise, Blood, Feinstein, Mouse, Hematoma, Medical research, FDA, Mental health, Injury, Medical device, Birth control

Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).

Key Points: 
  • Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).
  • Dr. Navid Khodaparast, Chief Science Officer of Spark and Five Liters stated “Von Willebrand Disease is an inherited bleeding disorder in which blood does not clot properly, leading to bleeding events and joint problems.
  • At Five Liters, our primary clinical initiative is to demonstrate that tAN therapy can safely alleviate menorrhagia in females with VWD.
  • Thanks to this partnership and the Nature article, Five Liters is thrilled to move forward with its mission.

Feinstein Institutes bioelectronic medicine researchers stimulate vagus nerve to reduce bleeding in hemophilia

Retrieved on: 
Thursday, June 1, 2023
Health, Neurology, Other Health, Clinical Trials, Research, Science, Biotechnology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Elmezzi Graduate School of Molecular Medicine, Communication, Medicine, Donald, Travel, Bleeding, Education, Diabetes, Inflammatory Bowel Diseases, Feinstein Institutes for Medical Research, Vagus nerve, Arthritis, Nature Communications, Cancer, Haemophilia, DRS, Vagus nerve stimulation, Multimedia, Brain, Inflammation, Northwell Health, Crohn's disease, Spleen, MD, Patient, Blood, Mouse, Coagulopathy, Paper, Bacteria, Heart rate, Haemophilia A, Pulmonary hypertension, Death, Virus, Medical research, Disease, Birth control, Dentistry

Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.

Key Points: 
  • Researchers at The Feinstein Institutes for Medical Research have shown that electrically stimulating the vagus nerve can reduce bleeding in preclinical hemophilic mice models – a finding that could translate into human patients.
  • The study, published in Nature Communications , builds on years of research into harnessing the vagus nerve through electrical stimulation, a foundation of bioelectronic medicine.
  • (Feinstein Institutes)
    Led by Jared Huston, MD , associate professor of surgery and science education at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Institute of Bioelectronic Medicine at the Feinstein Institutes, the research shows that vagus nerve stimulation reduces bleeding in hemophilia A mice to the same degree as replacing missing clotting factor – the current gold-standard therapy for patients living with hemophilia.
  • Huston’s new findings indicate it may be possible to stop life-threatening bleeding by stimulating the vagus nerve.”
    The Feinstein Institutes is known as the global scientific home of bioelectronic medicine because of early discoveries in its labs.

Feinstein Institutes’ Elmezzi Graduate School class of 2023 physician-scientists conferred

Retrieved on: 
Tuesday, May 30, 2023
Health, Hospitals, Health Technology, Health Insurance, Clinical Trials, Research, Science, VNS, Oncology, University, MD–PhD, Frontiers, University of Calgary, Feinstein Institutes for Medical Research, Nature Communications, Biomedical Research, DRS, Vagus nerve stimulation, Haemophilia, Multimedia, Medicine, Doctor of Philosophy, Cumming School of Medicine, Molecular medicine, Student, Patient, Physician, Weatherall Institute of Molecular Medicine, Thomas, Medical research, Nursing, Management, Elmezzi Graduate School of Molecular Medicine, MD, Immunology

The 2023 Commencement Exercises for the Elmezzi Graduate School of Molecular Medicine took place on May 25 at The Feinstein Institutes for Medical Research , where three graduate students were conferred with their PhD.

Key Points: 
  • The 2023 Commencement Exercises for the Elmezzi Graduate School of Molecular Medicine took place on May 25 at The Feinstein Institutes for Medical Research , where three graduate students were conferred with their PhD.
  • (Photo: Business Wire)
    The Elmezzi Graduate School of Molecular Medicine is a PhD program for physicians who wish to pursue careers in biomedical research.
  • The Elmezzi Graduate School of Molecular Medicine is supported in part by a generous endowment from The Thomas and Jeanne Elmezzi Foundation.
  • “The Elmezzi Graduate School of Molecular Medicine is a unique program that transforms physicians into physician-scientists,” said Annette T. Lee, PhD , dean of the Elmezzi Graduate School of Molecular Medicine.